drugset / Trial / NCT04242199

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors

NCT04242199

Phase 1 Completed 182 enrolled Incyte Corporation
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and early clinical activity of INCB099280 in participants with select solid tumors

Timeline

Start
2020-09-04
Primary completion
2024-08-29
Completion
2024-11-21

Drugs

EvaluationDrugModalityDoseRoute
Subject INCB099280 Unknown 25 mg Oral
Subject INCB099280 Unknown 100 mg Oral